JP2007522176A5 - - Google Patents

Download PDF

Info

Publication number
JP2007522176A5
JP2007522176A5 JP2006552565A JP2006552565A JP2007522176A5 JP 2007522176 A5 JP2007522176 A5 JP 2007522176A5 JP 2006552565 A JP2006552565 A JP 2006552565A JP 2006552565 A JP2006552565 A JP 2006552565A JP 2007522176 A5 JP2007522176 A5 JP 2007522176A5
Authority
JP
Japan
Prior art keywords
alkyl
compound according
hydrogen
alkenyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006552565A
Other languages
English (en)
Japanese (ja)
Other versions
JP5001012B2 (ja
JP2007522176A (ja
Filing date
Publication date
Priority claimed from GB0403282A external-priority patent/GB0403282D0/en
Priority claimed from GB0423562A external-priority patent/GB0423562D0/en
Priority claimed from GB0428375A external-priority patent/GB0428375D0/en
Application filed filed Critical
Priority claimed from PCT/EP2005/001449 external-priority patent/WO2005077950A2/en
Publication of JP2007522176A publication Critical patent/JP2007522176A/ja
Publication of JP2007522176A5 publication Critical patent/JP2007522176A5/ja
Application granted granted Critical
Publication of JP5001012B2 publication Critical patent/JP5001012B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006552565A 2004-02-14 2005-02-10 Ｈｍ７４ａ受容体活性を有する薬剤 Expired - Fee Related JP5001012B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0403282A GB0403282D0 (en) 2004-02-14 2004-02-14 Chemical compounds
GB0403282.7 2004-02-14
GB0423562A GB0423562D0 (en) 2004-10-22 2004-10-22 Novel compounds
GB0423562.8 2004-10-22
GB0428375.0 2004-12-24
GB0428375A GB0428375D0 (en) 2004-12-24 2004-12-24 Novel compounds
PCT/EP2005/001449 WO2005077950A2 (en) 2004-02-14 2005-02-10 Medicaments with hm74a receptor activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008030344A Division JP5020848B2 (ja) 2004-02-14 2008-02-12 Ｈｍ７４ａ受容体活性を有する薬剤

Publications (3)

Publication Number Publication Date
JP2007522176A JP2007522176A (ja) 2007-08-09
JP2007522176A5 true JP2007522176A5 (https=) 2008-04-03
JP5001012B2 JP5001012B2 (ja) 2012-08-15

Family

ID=34864831

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006552565A Expired - Fee Related JP5001012B2 (ja) 2004-02-14 2005-02-10 Ｈｍ７４ａ受容体活性を有する薬剤
JP2008030344A Expired - Fee Related JP5020848B2 (ja) 2004-02-14 2008-02-12 Ｈｍ７４ａ受容体活性を有する薬剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008030344A Expired - Fee Related JP5020848B2 (ja) 2004-02-14 2008-02-12 Ｈｍ７４ａ受容体活性を有する薬剤

Country Status (25)

Country Link
US (5) US7713982B2 (https=)
EP (1) EP1781657B1 (https=)
JP (2) JP5001012B2 (https=)
KR (1) KR101100601B1 (https=)
CN (2) CN101863888B (https=)
AR (1) AR047669A1 (https=)
AU (1) AU2005212816C1 (https=)
BR (1) BRPI0507604A (https=)
CA (1) CA2556073C (https=)
CY (1) CY1114022T1 (https=)
DK (1) DK1781657T3 (https=)
ES (1) ES2406732T3 (https=)
HR (1) HRP20130406T1 (https=)
IL (1) IL177051A (https=)
MA (1) MA28357A1 (https=)
MY (1) MY148937A (https=)
NO (1) NO337281B1 (https=)
NZ (1) NZ548496A (https=)
PE (1) PE20060317A1 (https=)
PL (1) PL1781657T3 (https=)
PT (1) PT1781657E (https=)
SG (1) SG157242A1 (https=)
SI (1) SI1781657T1 (https=)
TW (1) TWI350289B (https=)
WO (1) WO2005077950A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100390178C (zh) * 1999-11-12 2008-05-28 拜奥根Idec马萨诸塞公司 作为腺苷受体拮抗剂的多环烷基嘌呤
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
EP1603585A2 (en) 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
PL1781657T3 (pl) * 2004-02-14 2013-08-30 Glaxosmithkline Ip Dev Ltd Leki o aktywności wobec receptora HM74A
CN102633730A (zh) 2004-12-03 2012-08-15 先灵公司 作为cb1拮抗剂的取代哌嗪
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
US7750015B2 (en) 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7723342B2 (en) 2005-05-17 2010-05-25 Schering Corporation Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
BRPI0611784A2 (pt) 2005-06-14 2010-09-28 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem e utilização desses compostos
PT1901731E (pt) 2005-06-28 2011-05-11 Merck Sharp & Dohme Agonistas de receptor de niacina, composi??es que cont?m tais compostos e m?todos de tratamento
ES2401128T3 (es) * 2005-08-10 2013-04-17 Glaxosmithkline Llc Derivados de xantina como agonistas selectivos de HM74A
CA2637717A1 (en) * 2006-01-20 2007-08-02 Schering Corporation Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia
MX2008014689A (es) * 2006-05-23 2008-11-27 Hoffmann La Roche Derivados de piridopirimidininona.
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
MX2009000170A (es) 2006-06-23 2009-01-23 Incyte Corp Derivados de purinona como agonistas de hm74a.
MX2009000169A (es) 2006-06-23 2009-01-26 Incyte Corp Derivados de purinona como agonistas de hm74a.
MX2009010218A (es) * 2007-03-23 2009-10-19 Hoffmann La Roche Derivados de aza-piridopirimidinona.
DK2370440T3 (en) * 2008-12-08 2014-12-08 Glaxosmithkline Llc 8-Chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dion2-amino-2- (hydroxymethyl) -1,3-propandiolanhydrat for the treatment of diseases
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
CN102276610B (zh) * 2011-05-04 2013-01-09 北京工业大学 N7-鸟嘌呤烷化物的制备方法
CN103360394B (zh) * 2013-07-29 2015-07-22 上海万巷制药有限公司 8-氯茶碱的制备方法
EP3251675B1 (en) * 2015-01-30 2021-04-21 Shanton Pharma Pte. Ltd. Prevention or treatment of uric acid or gout disease
CN104892610B (zh) * 2015-05-27 2016-08-24 福建师范大学 一种8-酯基咖啡因衍生物的制备方法
CN105622610A (zh) * 2016-03-28 2016-06-01 浙江诚意药业股份有限公司 一种黄嘌呤化合物的制备方法
EP3490579B1 (en) 2016-07-27 2025-09-10 Hartis-Pharma SA Therapeutic combinations to treat red blood cell disorders
CN106632061B (zh) * 2016-11-23 2020-07-24 上海皓元医药股份有限公司 一种1-(4-苯基-1-烷基-1h-咪唑-2-基)乙酮及其衍生物的合成方法
AR113206A1 (es) 2017-01-10 2020-02-19 Bayer Cropscience Ag Derivados heterocíclicos como pesticidas
JP2022549807A (ja) * 2019-09-25 2022-11-29 ゴールドフィンチ バイオ，インク． キサンチンｃｂ１阻害物質
CN112724141A (zh) * 2021-01-21 2021-04-30 南京艾美斐生物医药科技有限公司 一种gpr109a蛋白受体抑制剂及其制备和应用
CN113262882B (zh) * 2021-07-21 2021-09-17 北京矿冶研究总院 阳离子捕收剂、制备方法及在磷矿反浮选中的应用
CN121219290A (zh) 2023-02-27 2025-12-26 珊顿医药科技新加坡公司 化合物8-氯-3-戊基-3,7-二氢-1h-嘌呤-2,6-二酮的晶型及其制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2797220A (en) * 1954-12-02 1957-06-25 Univ Michigan Substituted paraxanthines
US4847377A (en) * 1985-05-13 1989-07-11 Schering Corporation Substituted-2,3-dihydro-6-substituted-pyrimido[2,1-F]-purine-4,8(1H,9H)-diones
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
IL100088A (en) * 1990-11-21 1995-07-31 Smithkline Beecham Corp FNT inhibitor preparations containing histogenic transducts converted at positions 1, 3, and 8
WO1993016699A1 (en) * 1992-02-21 1993-09-02 Smithkline Beecham Corporation Tnf inhibitors
EP0584347B1 (en) 1992-03-04 2003-01-15 Cell Therapeutics, Inc. Enantiomeric hydroxylated xanthine compounds
US6693105B1 (en) 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US5473070A (en) 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
US5804584A (en) 1992-11-16 1998-09-08 Cell Therapeutics, Inc. Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms
US6469017B1 (en) 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
IL109161A0 (en) 1993-03-31 1994-06-24 Cell Therapeutics Inc Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
US5670506A (en) 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
WO1994024133A1 (en) 1993-04-09 1994-10-27 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
AU1868195A (en) 1994-01-28 1995-08-15 Cell Therapeutics, Inc. Cell signaling inhibitors
US6878715B1 (en) 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
US6780865B1 (en) 1994-02-18 2004-08-24 Cell Therapeutics, Inc. Compounds having selective hydrolytic potentials
JPH09511496A (ja) 1994-02-18 1997-11-18 セル・セラピューティックス・インコーポレーテッド 細胞内メッセンジャー
US6103730A (en) 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
US5807861A (en) 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US5801182A (en) 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
AR015966A1 (es) * 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
CA2369981A1 (en) 1999-04-09 2000-10-19 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same
US20030207901A1 (en) 1999-07-27 2003-11-06 Cell Therapeutics, Inc. Hydroxyl-containing compounds
DE60001969T2 (de) * 1999-08-31 2004-02-05 Vanderbilt University, Nashville Selektive antagonisten von a2b adenosinrezeptoren
US6855817B2 (en) * 2000-07-21 2005-02-15 Mark B. Lyles Materials and methods for binding nucleic acids to surfaces
FR2812482B1 (fr) * 2000-07-28 2003-01-24 Inside Technologies Dispositif electronique portable comprenant plusieurs circuits integres sans contact
EP1322306A2 (en) * 2000-09-19 2003-07-02 NovImmune S.A. Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
EP1368349B1 (de) 2001-02-24 2007-02-14 Boehringer Ingelheim Pharma GmbH & Co.KG Xanthinderivate, deren herstellung und deren verwendung als arzneimittel
EP1377834A2 (en) * 2001-04-11 2004-01-07 Glaxo Group Limited Medicaments which are modulators of hm74 and/or hm74a activity
PL1781657T3 (pl) 2004-02-14 2013-08-30 Glaxosmithkline Ip Dev Ltd Leki o aktywności wobec receptora HM74A
WO2006045564A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
US20090209561A1 (en) 2004-10-22 2009-08-20 Richard Jonathan Daniel Hatley Xanthine Derivatives with HM74A Receptor Activity
ES2401128T3 (es) 2005-08-10 2013-04-17 Glaxosmithkline Llc Derivados de xantina como agonistas selectivos de HM74A
EP1939197A1 (en) * 2006-12-22 2008-07-02 Schwarz Pharma Ag 8-ethinylxanthine derivatives as selective A2A receptor antagonists
DK2370440T3 (en) * 2008-12-08 2014-12-08 Glaxosmithkline Llc 8-Chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dion2-amino-2- (hydroxymethyl) -1,3-propandiolanhydrat for the treatment of diseases
US20110065676A1 (en) * 2009-06-24 2011-03-17 Schering Corporation Combination therapies comprising par1 antagonists with nar agonists

Similar Documents

Publication Publication Date Title
JP2007522176A5 (https=)
CA2556073A1 (en) 8-chloro-1,3-disubstituted xanthine derivatives as hm74a receptor modulators
US11013722B2 (en) Therapeutic agent for dyslipidemia
HRP20100725T1 (hr) Derivati ksantina kao selektivni agonisti hm74a
JP2025071236A (ja) 代謝機能不全によって引き起こされる腫瘍の治療
JP2007502263A5 (https=)
JP2015164964A5 (https=)
JP2016500063A5 (https=)
JP2011512856A5 (https=)
JP2011514379A (ja) 選択的ｓ１ｐ１レセプターアゴニストの投与法
US9458093B2 (en) Compositions for the treatment of hypertension and/or fibrosis
CN1454054A (zh) 用(r)－奥昔布宁和(r)－去乙基奥昔布宁治疗平滑肌机能亢进
CN101823956B (zh) 非诺贝特酸二异丙胺盐、其制备方法, 药物组合物及其用途
EP2945618A1 (en) Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders
RU2742418C1 (ru) Лекарственные формы, содержащие оксалатные соли тенелиглиптина и их сольваты
JP2016505039A5 (https=)
EP1882474A1 (en) Prophylactic/therapeutic agent for abnormalities of sugar/lipid metabolism
B Ghatak et al. Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus
JP2009506043A5 (https=)
RU2006132925A (ru) Новые соединения
JP2012511028A5 (https=)
WO2011141419A1 (en) Association of the xanthine oxidase inhibitor febuxostat and metformin and use thereof
US20240366596A1 (en) Treatment of hfpef in post-menopausal women with an sgc stimulator
JP2020520904A5 (https=)
EP4076463A1 (en) Use of lemborexant for treating insomnia